Clinical Trials Sponsored by Grupo Espanol Tratamiento Tumores Digestivos

Total 53 results

Grupo Español de Tratamiento de Tumores de Cabeza...

Completed

TPF Plus Cisplatin and Radiotherapy vs TPF Plus Cetuximab and Radiotherapy to Treat Head and Neck Cancer.

Head and Neck Cancer

Spain
Grupo Español de Tratamiento de Tumores de Cabeza...

Active, not recruiting

Spanish Study for Molecular Characterization of Thyroid Carcinoma (MOLTHY)

Differentiated Thyroid Carcinoma | Medullary Thyroid Carcinoma

Spain
Grupo Español de Tratamiento de Tumores de Cabeza...

Completed

TPF Plus Radiotherapy and Cetuximab to Avoid Total Laryngectomy in Patients With Larynx Cancer

Head and Neck Cancer

Spain
Grupo Espanol de Tumores Neuroendocrinos

Recruiting

Nutrition in Gastroenteropancreatic Neuroendocrine Tumor (NUTRIGETNE)

Gastroenteropancreatic Neuroendocrine Tumor

Spain
Grupo Espanol de Tumores Neuroendocrinos

Recruiting

GETNE Registration of Thyroid Cancer

Thyroid Cancer

Spain
Grupo Espanol de Tumores Neuroendocrinos

Active, not recruiting

Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.

Neuroendocrine Tumors | Neuroendocrine Neoplasm | Gastroenteropancreatic Neuroendocrine Tumor

Spain
Grupo Espanol de Tumores Neuroendocrinos

Completed

Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin (DUNE)

Neuroendocrine Tumors | Neuroendocrine Neoplasm of Lung

Spain
Grupo Espanol de Tumores Neuroendocrinos

Completed

Radiological Response of Pancreatic Neuroendocrine Tumors: Comparison Between the Choi and the RECIST Criteria (CRIPNET)

Pancreatic Neuroendocrine Tumors

Spain
Grupo Espanol de Tumores Neuroendocrinos

Completed

A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET) (PALBONET)

Pancreatic Neuroendocrine Cancer

Spain
Grupo Espanol de Tumores Neuroendocrinos

Completed

Phase II Study of Everolimus Combined With Octreotide LAR to Treat Advanced GI NET (EVERLAR)

Gastrointestinal Neoplasms

Spain
Grupo Espanol de Tumores Neuroendocrinos

Completed

Pazopanib as Single Agent in Advanced NETs

Advanced/Metastatic Neuroendocrine Tumors

Spain
Grupo Espanol de Tumores Neuroendocrinos
MFAR

Active, not recruiting

Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial (DUTHY)

Metastatic Thyroid Cancer | Metastatic Thyroid Papillary Carcinoma | Metastatic Thyroid Follicular Carcinoma

Spain
Grupo Espanol de Tumores Neuroendocrinos
Pfizer

Active, not recruiting

Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas

Neuroendocrine Tumors | Advanced Cancer

Spain, Germany, Italy, United Kingdom
Grupo Español de Tratamiento de Tumores de Cabeza...
GlaxoSmithKline; MFAR

Recruiting

Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma (RADIAN)

Head and Neck Squamous Cell Carcinoma

Spain
Grupo Espanol de Tumores Neuroendocrinos
Ipsen; MFAR

Recruiting

Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer. (CABOTHYROID)

Differentiated Thyroid Cancer

Spain
Grupo Espanol de Tumores Neuroendocrinos
Pfizer; Threshold Pharmaceuticals

Completed

A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours

Pancreatic Neoplasms | Neuroendocrine Tumors

Spain
Grupo Espanol Multidisciplinario del Cancer Digestivo

Completed

Avelumab Plus Autologous Dendritic Cell Vaccine in Pre-treated Metastatic Colorectal Cancer Patients (AVEVAC)

Colorectal Carcinoma

Spain
Grupo Espanol Multidisciplinario del Cancer Digestivo

Unknown

Efficacy/Safety Study of Bevacizumab,Capecitabine,Oxaliplatin to Metastatic Colorectal Adenocarcinoma Elderly Patients. (BECOX)

Metastatic Colorectal Cancer

Spain
Grupo Espanol Multidisciplinario del Cancer Digestivo

Completed

Study of Oxaliplatin and Sorafenib Combination to Treat Gastric Cancer Relapsed After a Cisplatin Based Treatment

Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (Relapsed After a Cisplatin Based Treatment)

Spain
Grupo Espanol Multidisciplinario del Cancer Digestivo

Recruiting

GEMCAD-REVEAL STUDY - Circulating Tumor DNA as a Predictor of Relapse in Patients With Locally Advanced Rectal Cancer. (REVEAL)

Patients With Locally Advanced Rectal Cancer

Spain
Grupo Espanol Multidisciplinario del Cancer Digestivo

Active, not recruiting

Observational Study to Evaluate the Use of Targeted Therapies in Metastatic Colorectal Cancer

Metastatic Colon Cancer

Spain
Grupo Espanol Multidisciplinario del Cancer Digestivo

Completed

Efficacy and Safety of a Neoadjuvant Treatment in Pancreatic Cancer (GEMCAD1003)

Pancreatic Adenocarcinoma

Spain
Grupo Espanol Multidisciplinario del Cancer Digestivo

Completed

Phase I-II to Evaluate Efficacy/Safety of Sorafenib+Gemcitabine+Radiotherapy in Locally Advanced Pancreatic Carcinoma

Pancreatic Cancer

Spain
Grupo Espanol de Tumores Neuroendocrinos
Gilead Sciences; MFAR

Not yet recruiting

Sacituzumab govitEcan in THYroid Cancers (SETHY)

Differentiated Thyroid Cancer | Anaplastic Thyroid Cancer

Spain
Grupo Español de Tumores Huérfanos e Infrecuentes

Terminated

Ketoconazole as Inhibitor of the Enzyme CYP17 in Locally Advanced or Disseminated Granulosa Cell Tumour of Ovary (GreKo)

Granulosa Cell Tumour of the Ovary

Spain
Grupo Espanol Multidisciplinario del Cancer Digestivo

Recruiting

Chemoembolization (Lifepearls-Irinotecan) in Patients With Colorectal Cancer and Metastatic Disease (LIVERPEARL)

Colorectal Cancer Metastatic | Liver Metastasis Colon Cancer

Spain
Grupo Espanol Multidisciplinario del Cancer Digestivo

Completed

Study Evaluating Biomarkers in Patients With Colorectal Cancer and Native KRAS Treated With Chemotherapy + Cetuximab (POSIBA)

Colorectal Cancer

Spain
Grupo Espanol Multidisciplinario del Cancer Digestivo

Completed

Correlation Between RECIST, Morphologic Response by CT- Histopathologic Response in Hepatic Metastasis Secondary to Colorectal Cancer (AVAMET)

Colorectal Cancer | Hepatic Metastasis

Spain
Grupo Español de Tratamiento de Tumores de Cabeza...
Amgen; Trial Form Support S.L.

Completed

Study of the Combination of Panitumumab With Paclitaxel as First-line Treatment of Subjects With Head and Neck Cancer (VECTITAX)

Head and Neck Cancer

Spain
Grupo Español de Tratamiento de Tumores de Cabeza...
Merck Sharp & Dohme LLC; Pivotal S.L.

Terminated

Paclitaxel vs Paclitaxel + Cetuximab in Recurrent - Metastatic Head & Neck Carcinoma After Failure of a 1º Chemotherapy (EXTAX)

Head and Neck Cancer
Grupo Español de Tumores Huérfanos e Infrecuentes
Takeda

Terminated

Orteronel (TAK-700) in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors. The Greko II Study. (Greko II)

Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors

Spain
Grupo Espanol de Tumores Neuroendocrinos
Pfizer; Apices Soluciones S.L.

Completed

Efficacy of Rechallenge With Sunitinib in Metastatic Pancreatic Neuroendocrine Tumor Previously Failed to Sunitinib (RESUNET)

Pancreatic Neuroendocrine Tumour Metastatic

Spain
Grupo Espanol de Tumores Neuroendocrinos
Roche Pharma AG; Ipsen

Active, not recruiting

Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study (CABATEN)

Adenocarcinoma | Neuroendocrine Tumor | Pheochromocytoma | Paraganglioma | Anaplastic Thyroid Cancer

Spain
Grupo Espanol de Tumores Neuroendocrinos
MFAR; ITM Oncologics GmbH

Recruiting

Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus. (LEVEL)

Thymus Neoplasms | Neuroendocrine Tumors | Lung Neuroendocrine Neoplasm

Spain, Italy, France
Grupo Espanol de Tumores Neuroendocrinos
Eisai Limited; Experior S.L.

Completed

Lenvatinib Efficacy in Metastatic Neuroendocrine Tumors (TALENT)

Neuroendocrine Tumors

Spain, Italy, Austria, United Kingdom
Grupo Espanol de Tumores Neuroendocrinos
Novartis Pharmaceuticals; European Neuroendocrine Tumor Society; Kantar Health

Completed

Efficacy and Safety of Everolimus and (STZ-5FU) Given One Upfront the Other Upon Progression in Advanced Pancreatic Neuroendocrine Tumor (pNET) (SEQTOR)

Neuroendocrine Tumors

Spain, United Kingdom, Denmark, France, Netherlands, Germany, Italy, Sweden
Grupo Español de Tratamiento de Tumores de Cabeza...
Bristol-Myers Squibb; Apices Soluciones S.L.

Active, not recruiting

Study to Assess the Efficacy and Safety of Nivolumab in Combination With Paclitaxel in Subjects With Head and Neck Cancer Unable for Cisplatin-based Chemotherapy (NIVOTAX) (NIVOTAX)

Recurrent Head and Neck Squamous Cell Carcinoma | Head and Neck Cancer Stage IV

Spain
Robert Roessle Klinik
Federation Francophone de Cancerologie Digestive; European Organisation for... and other collaborators

Completed

High-Dose Fluorouracil With or Without Leucovorin Compared With Standard Fluorouracil Plus Leucovorin Following Surgery in Treating Patients With Stage III Colon Cancer

Colorectal Cancer

France, Spain, Belgium, Netherlands, Serbia, Germany
Grupo Espanol Multidisciplinario del Cancer Digestivo
Pivotal S.L.

Completed

Induction FOLFOX With or Without Aflibercept Followed by Chemoradiation in High Risk Locally Advanced Rectal Cancer (RIA)

Rectal Cancer
Grupo Espanol Multidisciplinario del Cancer Digestivo
Hoffmann-La Roche

Recruiting

Tiraglolumab Atezolizumab and Chemoradiotherapy in Localized Anal Carcinoma (TIRANUS) (TIRANUS)

Squamous Cell Carcinoma of the Anal Canal

Spain
Groupe Oncologie Radiotherapie Tete et Cou
AIO-Studien-gGmbH; Grupo Español de Tratamiento de Tumores de Cabeza y Cuello

Completed

Platinum-Cetuximab Combined With Docetaxel or With 5FU in Patients With Recurrent/Metastatic HNSCC (TPExtreme)

Head and Neck Squamous Cell Carcinoma

France, Germany, Spain
Grupo Espanol Multidisciplinario del Cancer Digestivo
Amgen; Pivotal S.L.

Completed

Induction Therapy With Panitumumab + mFOLFOX-6 in Rectal Cancer and Quadruple Wild-type Mutation Before Surgery (PIER)

Rectal Cancer

Spain
Grupo Espanol Multidisciplinario del Cancer Digestivo
Amgen; Pivotal S.L.

Completed

FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF Wild-type and Good Performance Status (OPALO)

Neoplasm Metastasis | Colorectal Neoplasms | Colorectal Cancer Metastatic | Colorectal Carcinoma

Spain
Grupo Espanol Multidisciplinario del Cancer Digestivo
Amgen; Pivotal S.L.

Active, not recruiting

Second-line FOLFIRI + Panitumumab in Subjects With Wild Type RAS Metastatic Colorectal (BEYOND)

Colorectal Cancer Metastatic

Spain
Grupo Español de Tratamiento de Tumores de Cabeza...
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt...

Completed

Cetuximab Plus Paclitaxel as First Line for Recurrent and/or Metastatic SCCHN: Real World Data.

Squamous Cell Carcinoma of the Head and Neck

Spain
Grupo Espanol Multidisciplinario del Cancer Digestivo
Royal Marsden NHS Foundation Trust

Completed

Study of Neoadjuvant CT With Selective Radiotherapy in Patients With Intermediate-Risk Cancer Rectum

Rectum Cancer

Spain
Grupo Espanol Multidisciplinario del Cancer Digestivo
Merk Sharp & Dohme España S.A.

Recruiting

Pembrolizumab and Olaparib in Homologous-recombination Deficient (HRD) Advanced Colorectal Cancer (CRC). (PEMBROLA)

Metastatic Colorectal Cancer

Spain
Grupo Espanol Multidisciplinario del Cancer Digestivo
Amgen; TFS Trial Form Support

Completed

Study Assessing Potential Predictive Tumor Markers in Metastatic Colorectal Cancer (PULSE)

Metastatic Colorectal Cancer

Spain
Grupo Espanol Multidisciplinario del Cancer Digestivo
Amgen; Trial Form Support S.L.

Completed

Vectibix for the Treatment of Anal Cancer (VITAL)

Anal Squamous Cell Carcinoma

Spain
Grupo Español de Tumores Huérfanos e Infrecuentes
Astellas Pharma Inc; Apices Soluciones S.L.

Completed

Enzalutamide in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors: GREKO III Study (GREKO III)

Ovarian Cancer

Spain

Clinical Trials Sponsored by Grupo Espanol Tratamiento Tumores Digestivos

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saint Lucia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations